Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Papers published on a yearly basis
Papers
More filters
••
Princess Margaret Cancer Centre1, Hebron University2, Sheba Medical Center3, University of Glasgow4, University of Washington5, Memorial Sloan Kettering Cancer Center6, University of Texas MD Anderson Cancer Center7, Ohio State University8, Institut Gustave Roussy9, University of California, San Francisco10, Université de Montréal11, University of Cambridge12, University of California, Los Angeles13, Harvard University14, Foundation Medicine15, University College London16
TL;DR: Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety profile and investigator-assessed confirmed objective response rate (ORR).
205 citations
••
European Institute of Oncology1, The Royal Marsden NHS Foundation Trust2, Carlos III Health Institute3, University of Valencia4, University of Milan5, University of Alcalá6, Claude Bernard University Lyon 17, Curie Institute8, Netherlands Cancer Institute9, Heidelberg University10, Leipzig University11, Cliniques Universitaires Saint-Luc12, University of Lausanne13, Hebron University14, University of Ioannina15, University of Geneva16, Université Paris-Saclay17, Harvard University18, Duke University19, National University of Singapore20, Université libre de Bruxelles21, Lund University22, Institut Gustave Roussy23, Vita-Salute San Raffaele University24
TL;DR: An international consortium to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic agreed on 28 consensus statements that can be used to overcome many of the clinical and technical areas of uncertainty.
203 citations
••
University of Colorado Boulder1, Yonsei University2, Samsung Medical Center3, National Taiwan University4, Chungbuk National University5, Seoul National University Hospital6, University of Oldenburg7, Hebron University8, University of Manchester9, Yale Cancer Center10, Millennium Pharmaceuticals11, The Royal Marsden NHS Foundation Trust12, Institute of Cancer Research13
TL;DR: Brigatinib represents a once-daily ALK inhibitor with superior efficacy, tolerability, and QoL over crizotinib, making it a promising first-line treatment of ALK-positive NSCLC.
Abstract: PURPOSEBrigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizo...
203 citations
••
TL;DR: The role of intratumoral heterogeneity is highlighted, focusing on the clinical and biological ramifications this phenomenon poses, and how understanding the involved drivers and functional consequences can provide novel insight needed to confront the problem of therapeutic resistance in tumors.
Abstract: In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. Functionally, heterogeneity provides tumors with significant adaptability. This ranges from mutual beneficial cooperation between cells, which nurture features such as growth and metastasis, to the narrow escape and survival of clonal cell populations that have adapted to thrive under specific conditions such as hypoxia or chemotherapy. These dynamic intercellular interplays are guided by a Darwinian selection landscape between clonal tumor cell populations and the tumor microenvironment. Understanding the involved drivers and functional consequences of such tumor heterogeneity is challenging but also promises to provide novel insight needed to confront the problem of therapeutic resistance in tumors.
202 citations
••
TL;DR: Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107, and the maximum tolerated dose using this schedule is 4.0 mg/m2.
Abstract: Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule. Experimental Design: Patients with solid tumors refractory to standard therapies or with no standard treatment available were enrolled. Dose levels of 0.6 to 4.5 mg/m 2 were explored. Results: Forty patients [24M/16F, median age 61 years (45–79)] were enrolled. At 4.5 mg/m 2 , dose-limiting toxicity (DLT) consisted of grade 3 diarrhea, nausea, and vomiting and grade 4 diarrhea, respectively, in two patients. At 4.0 mg/m 2 , DLT (grade 3 nausea, vomiting, and abdominal cramps) was observed in one patient. Frequently occurring side effects were mainly gastrointestinal. After drug discontinuation at 4.0 mg/m 2 , one patient experienced reversible grade 4 blurred vision. The maximum tolerated dose (MTD) is 4.0 mg/m 2 . No complete or partial responses during treatment were observed; one patient at 4.0 mg/m 2 had a confirmed partial response after drug discontinuation. Pharmacokinetic analysis revealed a large volume of distribution, high systemic clearance, and a plasma elimination half-life of 5.3 to 15.1 hours. Overall drug exposure increased in a dose-dependent manner. At the MTD, mRNA levels of selected target genes monitored in peripheral blood mononuclear cells showed a reversible 15- to 25-fold decrease, whereas unspliced pre-mRNA levels of DNAJB1 and EIF4A1 showed a reversible 10- to 25-fold increase. Conclusion: The MTD for E7107 using this schedule is 4.0 mg/m 2 . Pharmacokinetics is dose-dependent and reproducible within patients. Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107. Clin Cancer Res; 19(22); 6296–304. ©2013 AACR .
201 citations
Authors
Showing all 2723 results
Name | H-index | Papers | Citations |
---|---|---|---|
José Baselga | 156 | 707 | 122498 |
M. I. Martínez | 134 | 1251 | 79885 |
Josep Tabernero | 111 | 803 | 68982 |
Jordi Rello | 103 | 694 | 35994 |
Xavier Montalban | 95 | 762 | 52842 |
James M. Downey | 91 | 381 | 29506 |
Enriqueta Felip | 83 | 622 | 53364 |
Joaquim Bellmunt | 82 | 660 | 41472 |
Joan Montaner | 80 | 489 | 22413 |
Marc Miravitlles | 76 | 651 | 25671 |
David H. Salat | 75 | 241 | 36779 |
Eduard Gratacós | 75 | 531 | 20178 |
Alex Rovira | 74 | 356 | 19586 |
Ramon Bataller | 72 | 283 | 19316 |
Maria Buti | 71 | 493 | 26596 |